Quarterly report pursuant to Section 13 or 15(d)

Selected Balance Sheet Data

v3.24.0.1
Selected Balance Sheet Data
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Selected Balance Sheet Data

Note 3. Selected Balance Sheet Data:

Inventories:

Inventories consist of (in thousands):

    

December 31, 

June 30, 

    

2023

    

2023

Raw materials

$

83,247

$

84,551

Finished goods(1)

 

102,907

 

92,474

Inventories, net

$

186,154

$

177,025

(1) Finished goods inventory of $5,315 and $5,387 included within Other long-term assets in the respective December 31, 2023 and June 30, 2023, Consolidated Balance Sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Property and Equipment:

Property and equipment consist of (in thousands):

    

December 31, 

June 30, 

    

2023

    

2023

Land

$

8,180

$

9,100

Buildings and improvements

 

243,640

 

245,302

Machinery and equipment

199,533

190,019

Construction in progress

 

28,065

 

15,491

Property and equipment, cost

 

479,418

 

459,912

Accumulated depreciation and amortization

 

(245,214)

 

(233,712)

Property and equipment, net

$

234,204

$

226,200

Intangible Assets:

Intangible assets consist of (in thousands):

December 31, 

June 30, 

2023

2023

Developed technology

$

657,192

$

616,311

Trade names

 

152,206

 

146,945

Customer relationships

 

211,733

 

213,878

Patents

 

4,080

 

3,815

Other intangibles

 

11,865

 

11,566

Definite-lived intangible assets

 

1,037,076

 

992,515

Accumulated amortization

 

(509,171)

 

(480,570)

Definite-lived intangibles assets, net

 

527,905

 

511,945

In process research and development

 

22,700

 

22,700

Total intangible assets, net

$

550,605

$

534,645

Changes to the carrying amount of net intangible assets for the period ended December 31, 2023 consist of (in thousands):

Beginning balance

$

534,645

Acquisitions

 

66,400

Other additions

 

556

Held-for-sale intangibles(1)

(14,323)

Amortization expense

 

(40,383)

Currency translation

3,710

Ending balance

$

550,605

(1) Refer to Note 1 for further detail on held-for-sale intangibles.

The estimated future amortization expense for intangible assets as of December 31, 2023 is as follows (in thousands):

Remainder 2024

    

$

39,332

2025

 

75,553

2026

 

71,575

2027

 

61,394

2028

 

57,733

Thereafter

 

222,318

Total

$

527,905

Goodwill:

Changes to the carrying amount of goodwill for the period ended December 31, 2023 consist of (in thousands):

    

    

Diagnostics and

    

Protein Sciences

 Genomics

Total

June 30, 2023

$

427,027

$

445,710

$

872,737

Acquisitions

 

102,546

102,546

Held-for-sale goodwill(1)

(1,400)

(1,400)

Currency translation

 

318

5,881

6,199

December 31, 2023

$

425,945

$

554,137

$

980,082

(1)Refer to Note 1 for further detail on goodwill reclassified to current assets held-for-sale.

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a qualitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2023. No indicators of impairment were identified as part of our assessment.

Other Assets:

Other assets consist of (in thousands):

    

December 31, 

June 30, 

    

2023

2023

Investment in Wilson Wolf

$

249,730

$

255,857

Derivative instruments

11,589

16,857

Long-term inventory

5,315

5,387

Other

 

7,725

 

7,201

Other assets

$

274,359

$

285,302